Scarica l'app Stockscreener
1.54
0.65%
0.01
Dopo l'orario di chiusura:
1.49
-0.05
-3.25%
Precedente Chiudi:
$1.53
Aprire:
$1.52
Volume 24 ore:
1.91M
Relative Volume:
0.99
Capitalizzazione di mercato:
$177.61M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.9333
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
-4.35%
1M Prestazione:
+61.99%
6M Prestazione:
+46.67%
1 anno Prestazione:
-52.02%
Intervallo 1D:
$1.48
$1.65
Intervallo di 1 settimana:
$1.30
$1.66
Portata 52W:
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.54 | 172.99M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsWeekly Market Report & Daily Technical Stock Forecast Reports - newser.com
Using fundamentals and technicals on Fate Therapeutics Inc.Earnings Beat & Daily Market Momentum Tracking - newser.com
Is Fate Therapeutics Inc. stock reversal real or fakeMarket Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Why Fate Therapeutics Inc. stock remains a top recommendationTrade Exit Report & Verified Short-Term Trading Plans - newser.com
Is Fate Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Published on: 2025-10-14 21:30:26 - newser.com
FATE appoints Kamal Adawi CFO as board reduces from 10 to 8 - Stock Titan
Fate Therapeutics, Inc. Appoints Kamal Adawi as Chief Financial Officer, Effective October 20, 2025 - MarketScreener
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - GlobeNewswire
375,000-option grant leads Fate Therapeutics' appointment of Kamal Adawi as CFO, effective Oct 20, 2025 - Stock Titan
Automated trading signals detected on Fate Therapeutics Inc.Trade Exit Summary & Reliable Price Breakout Alerts - newser.com
Advanced analytics toolkit walkthrough for Fate Therapeutics Inc.Options Play & Community Driven Trade Alerts - newser.com
Published on: 2025-10-13 07:01:23 - newser.com
What technical signals suggest for Fate Therapeutics Inc. stockJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
What’s next for Fate Therapeutics Inc. stock priceWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Risk vs reward if holding onto Fate Therapeutics Inc.July 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Historical volatility pattern of Fate Therapeutics Inc. visualizedEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Real time social sentiment graph for Fate Therapeutics Inc.Trade Volume Report & Verified Entry Point Signals - newser.com
Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Fate Therapeutics, Inc. $FATE Stock Holdings Lessened by Public Employees Retirement System of Ohio - Defense World
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Is Fate Therapeutics Inc. stock in correction or buying zoneJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Chart based analysis of Fate Therapeutics Inc. trendsMarket Activity Report & Real-Time Market Trend Scan - newser.com
Fate Therapeutics Inc. stock daily chart insightsPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
What analysts say about Fate Therapeutics Inc stockPrice Gap Trading Strategies & Big Returns, Small Investment – Learn How - earlytimes.in
Detecting price anomalies in Fate Therapeutics Inc. with AI2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Is Fate Therapeutics Inc. stock trading at a premium valuationFed Meeting & Real-Time Buy Signal Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards under Nasdaq Listing Rule 5635(4) - MarketScreener
Should you hold or exit Fate Therapeutics Inc. now2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Fate Therapeutics Inc.July 2025 Price Swings & High Return Trade Guides - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule - MarketScreener
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year - simplywall.st
Is Fate Therapeutics Inc a good long term investmentCandlestick Trading Patterns & Minimal Capital Growth Plans - earlytimes.in
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fate Therapeutics Inc Azioni (FATE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):